Dr. Reddy's Laboratories Limited (RDY) Stock Forecast
RDY analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.60 / 5 from 5 analysts
- Price target
- $13.83 average of analyst targets
- Upside to target
- +5.8% from the latest close
- Next earnings
- October 23, 2026 EPS estimate $0.16
- 52-week range
- $11.38 – $15.38
RDY analyst ratings
5 analystsNumber of analysts at each rating.
RDY price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RDY earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current fiscal year (FY2027) | $43.85 | $43.85 | $43.85 | $55.39 | −20.8% | 1 |
| Next fiscal year (FY2028) | $62.08 | $62.08 | $62.08 | $43.85 | +41.6% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RDY revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $85.94B | $83.12B | $91.93B | −2.4% | 24 |
| Next quarter (Dec '26) | $89.85B | $88.16B | $93.05B | +3.0% | 5 |
| Current fiscal year (FY2027) | $351.92B | $336.37B | $373.52B | +4.8% | 35 |
| Next fiscal year (FY2028) | $393.11B | $376.20B | $437.39B | +11.7% | 33 |
RDY EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RDY revenue: reported and forecast
RDY EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current fiscal year (FY2027) | $0.00 | $51.40 | $51.04 | $51.04 | $43.85 | — | 0 up · 1 down |
| Next fiscal year (FY2028) | $0.00 | $64.96 | $63.32 | $63.32 | $62.08 | — | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RDY earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RDY beat in 7 of 12.
What analysts expect from RDY
5 analysts cover Dr. Reddy's Laboratories; their consensus rating is buy (3.60 on a 1–5 scale, where 5 is a strong buy). The average price target is $13.83, 5.8% above the latest close of $13.07. Analysts expect earnings of $43.85 per share for FY2027, −20.8% from a year earlier. For FY2028 the average estimate is $62.08 per share on revenue of $393.1 billion. Dr. Reddy's Laboratories beat the EPS estimate in 7 of the last 12 quarters.
Related: RDY income statement, RDY key metrics, RDY chart. See the RDY stock overview for the latest quote and news.
RDY forecast FAQ
What is Dr. Reddy's Laboratories's price target?
The average analyst price target for Dr. Reddy's Laboratories is $13.83, 5.8% above the latest close of $13.07.
Is Dr. Reddy's Laboratories a buy, hold or sell?
Of 5 analysts covering Dr. Reddy's Laboratories, 2 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Dr. Reddy's Laboratories's EPS forecast?
Analysts forecast $43.85 per share for FY2027 (range $43.85 to $43.85); for FY2028 the estimate is $62.08.
What is Dr. Reddy's Laboratories's revenue forecast?
The average revenue estimate for FY2027 is $351.9 billion, growth of 4.8%; for FY2028 it is $393.1 billion.
When does Dr. Reddy's Laboratories report earnings?
Dr. Reddy's Laboratories is expected to report results for the quarter ending September 30, 2026 on October 23, 2026 before the market opens; the EPS estimate is $0.16.
Does Dr. Reddy's Laboratories usually beat earnings estimates?
Dr. Reddy's Laboratories reported EPS at or above the analyst estimate in 7 of the last 12 quarters.